
Tardive dyskinesia - Pipeline Insight, 2024
Description
Tardive dyskinesia - Pipeline Insight, 2024
DelveInsight’s, Tardive dyskinesia - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Tardive dyskinesia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Tardive dyskinesia: Overview
Tardive dyskinesia (TD) is a syndrome that encompasses a constellation of iatrogenic movement disorders caused by antagonism of dopamine receptors. The movement disorders include akathisia, dystonia, buccolingual stereotypy, chorea, tics, and other abnormal involuntary movements. Most often, these dyskinetic disorders precipitate following chronic antipsychotic administration, however, several other medications are also associated with tardive dyskinesia. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM V) defines tardive dyskinesia as a medication-induced movement disorder that persists despite discontinuation or change of the medications. As per DSM-V, to confirm a diagnosis of tardive dyskinesia, symptoms must persist for at least one month after discontinuation of the medication.
""Tardive dyskinesia - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tardive dyskinesia pipeline landscape is provided which includes the disease overview and Tardive dyskinesia treatment guidelines. The assessment part of the report embraces, in depth Tardive dyskinesia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tardive dyskinesia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence R&D Tardive dyskinesia. The therapies under development are focused on novel approaches to treat/improve Tardive dyskinesia.
- SOM3366: SOM Biotech
Further product details are provided in the report……..
Tardive dyskinesia: Therapeutic Assessment
This segment of the report provides insights about the Tardive dyskinesia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Tardive dyskinesia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Molecule Type
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Tardive dyskinesia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tardive dyskinesia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tardive dyskinesia drugs.
Tardive dyskinesia Report Insights
- Tardive dyskinesia Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Tardive dyskinesia drugs?
- How many Tardive dyskinesia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tardive dyskinesia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tardive dyskinesia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Tardive dyskinesia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Addex Therapeutics
- Contera Pharma
- Teva Pharmaceutical
- SOM Biotech
- Mitsubishi Tanabe Pharma
- Dipraglurant
- CP-011
- Deutetrabenazine
- SOM3366
- MT-5199
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Tardive dyskinesia: Overview
- What is Tardive dyskinesia?
- Types of Tardive dyskinesia
- Causes
- Epidemiology and Risk Factors
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Tardive dyskinesia– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Deutetrabenazine: Teva Pharmaceutical
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II/III)
- Comparative Analysis
- MT-5199: Mitsubishi Tanabe Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Comparative Analysis
- CP-011: Contera Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Tardive dyskinesia Key Companies
- Tardive dyskinesia Key Products
- Tardive dyskinesia- Unmet Needs
- Tardive dyskinesia- Market Drivers and Barriers
- Tardive dyskinesia- Future Perspectives and Conclusion
- Tardive dyskinesia Analyst Views
- Tardive dyskinesia Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.